Study of ATEGE [antithymocyte globulin]-Fresenius induction in liver transplantation followed by tacrolimus weaning.

Trial Profile

Study of ATEGE [antithymocyte globulin]-Fresenius induction in liver transplantation followed by tacrolimus weaning.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Antithymocyte globulin (Primary) ; Tacrolimus (Primary) ; Methylprednisolone; Prednisone
  • Indications Liver transplant rejection
  • Focus Therapeutic Use
  • Acronyms ATEGE-LIVER
  • Most Recent Events

    • 26 May 2009 Planned end date (1 Jul 2009) added as reported by ClinicalTrials.gov.
    • 26 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 20 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top